MA43879A - Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridones - Google Patents

Modulation des rã‰cepteurs couplã‰s aux protã‰ines g (rcpg) par les imipridones

Info

Publication number
MA43879A
MA43879A MA043879A MA43879A MA43879A MA 43879 A MA43879 A MA 43879A MA 043879 A MA043879 A MA 043879A MA 43879 A MA43879 A MA 43879A MA 43879 A MA43879 A MA 43879A
Authority
MA
Morocco
Prior art keywords
imipridones
gpcr
modulation
receptors
protected
Prior art date
Application number
MA043879A
Other languages
English (en)
Other versions
MA43879B1 (fr
Inventor
Joshua E Allen
Varun Vijay Prabhu
Martin Stogniew
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/015817 external-priority patent/WO2016123571A1/fr
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of MA43879A publication Critical patent/MA43879A/fr
Publication of MA43879B1 publication Critical patent/MA43879B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
MA43879A 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones MA43879B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2016/015817 WO2016123571A1 (fr) 2015-01-30 2016-01-29 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogues et sels de ce composé et leur utilisation en thérapie
US201662308325P 2016-03-15 2016-03-15
US201662425403P 2016-11-22 2016-11-22
PCT/US2017/015608 WO2017132661A2 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones
EP17745078.0A EP3408298B1 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Publications (2)

Publication Number Publication Date
MA43879A true MA43879A (fr) 2018-12-05
MA43879B1 MA43879B1 (fr) 2025-02-28

Family

ID=59398848

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43879A MA43879B1 (fr) 2016-01-29 2017-01-30 Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones

Country Status (25)

Country Link
US (2) US11116771B2 (fr)
EP (2) EP4524567A3 (fr)
JP (3) JP7030701B2 (fr)
KR (2) KR20250065717A (fr)
CN (2) CN115844895B (fr)
AU (2) AU2017211423B2 (fr)
BR (1) BR112018015590A2 (fr)
CA (2) CA3294566A1 (fr)
DK (1) DK3408298T3 (fr)
ES (1) ES3012491T3 (fr)
FI (1) FI3408298T3 (fr)
HR (1) HRP20250207T1 (fr)
HU (1) HUE070208T2 (fr)
IL (3) IL286923B2 (fr)
LT (1) LT3408298T (fr)
MA (1) MA43879B1 (fr)
MX (2) MX2018009227A (fr)
NZ (1) NZ745425A (fr)
PL (1) PL3408298T3 (fr)
PT (1) PT3408298T (fr)
RS (1) RS66519B1 (fr)
SG (2) SG11201806401YA (fr)
SI (1) SI3408298T1 (fr)
SM (1) SMT202500086T1 (fr)
WO (1) WO2017132661A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3408298T3 (en) * 2016-01-29 2025-03-03 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2019055835A1 (fr) * 2017-09-15 2019-03-21 The Regents Of The University Of California Détection de variants mononucléotidiques somatiques à partir d'acide nucléique acellulaire avec application à une surveillance de maladie résiduelle minimale
US11674963B2 (en) 2017-09-27 2023-06-13 The Regents Of The University Of California GPCRs in cancer-associated fibroblasts
CA3089864A1 (fr) 2018-01-31 2019-08-08 Mayo Foundation For Medical Education And Research Methodes de traitement de pathologies fibrotiques
JP2021521141A (ja) * 2018-04-09 2021-08-26 オージェネシス インコーポレイテッド バイオキソーム粒子、レドキソーム、それらの作製方法、及びそれらを含む組成物
CN109157656B (zh) * 2018-10-15 2021-08-27 重庆医科大学附属永川医院 一种双靶标肿瘤疫苗及其制备方法和应用
JP2022520997A (ja) * 2019-02-22 2022-04-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム イミプリドンを使用する方法
KR20220041847A (ko) 2019-07-30 2022-04-01 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 섬유성 병리를 치료하기 위한 화합물 및 방법
KR102403686B1 (ko) 2020-05-15 2022-05-31 뉴로핏 주식회사 뇌자극 위치 제공장치 및 방법
MX2023001576A (es) 2020-08-06 2023-05-09 Eoetvoes Lorand Tudomanyegyetem Síntesis de nuevos derivados de imipridona y su evaluación de su actividad anticáncerigena.
CN112402439A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备改善肝胶原沉积相关产品中的应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
CA3263639A1 (fr) * 2022-08-03 2024-02-08 Xiandong SHI Procédé quantitatif pour déterminer un état mental fondé sur drd1 et/ou drd5, et son application
CN115531378B (zh) * 2022-10-19 2023-10-13 中国医学科学院医药生物技术研究所 Pht427作为ndm-1与kpc-2双重抑制剂的应用
WO2024157207A1 (fr) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Inhibiteurs de gpcr et leurs utilisations
EP4698146A1 (fr) * 2023-04-20 2026-02-25 Institut Gustave-Roussy Compositions liquides et solides de dérivés de l'imipridone
CN116731136B (zh) * 2023-08-04 2023-12-05 齐鲁工业大学(山东省科学院) H3k23a组蛋白点突变在提高酿酒酵母乙酸耐受性及木糖发酵性能中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
WO2004014909A1 (fr) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives fusionnes de la tetrahydropyridine inhibiteurs de la metalloprotease matricielle
WO2004082570A2 (fr) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics et traitements contre des maladies associees au recepteur d2 de la dopamine (drd2)
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2009039207A1 (fr) 2007-09-19 2009-03-26 Oncofluor, Inc. Procédé d'imagerie et de traitement d'organes et de tissus
JP2014509323A (ja) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
SMT202000272T1 (it) * 2011-04-29 2020-07-08 Penn State Res Found Induzione del gene trail da parte di cellule normali e tumorali mediante una piccola molecola come terapia anticancro
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
KR20220123335A (ko) 2013-03-13 2022-09-06 온코슈틱스 인코포레이티드 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
WO2015073072A1 (fr) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-méthylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
ES2724331T3 (es) 2013-11-15 2019-09-10 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso
ES2999685T3 (en) * 2014-03-31 2025-02-26 Scripps Research Inst Pharmacophore for trail induction
MD3805222T2 (ro) * 2015-01-30 2025-04-30 Oncoceutics Inc Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
DK3408298T3 (en) * 2016-01-29 2025-03-03 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Also Published As

Publication number Publication date
AU2022200583A1 (en) 2022-02-24
DK3408298T3 (en) 2025-03-03
CN109311980B (zh) 2023-01-17
RS66519B1 (sr) 2025-03-31
JP7825984B2 (ja) 2026-03-09
EP4524567A3 (fr) 2025-07-23
KR102801670B1 (ko) 2025-04-25
CA3294566A1 (en) 2026-03-02
AU2017211423B2 (en) 2021-10-28
JP2022046528A (ja) 2022-03-23
KR20180125460A (ko) 2018-11-23
SG11201806401YA (en) 2018-08-30
CN115844895B (zh) 2025-10-17
SG10202108306UA (en) 2021-08-30
EP4524567A2 (fr) 2025-03-19
NZ745425A (en) 2023-03-31
MX2023004443A (es) 2023-05-08
IL260815B (en) 2021-10-31
IL286923B2 (en) 2025-04-01
HRP20250207T1 (hr) 2025-04-11
WO2017132661A2 (fr) 2017-08-03
NZ784773A (en) 2025-05-02
LT3408298T (lt) 2025-03-10
KR20250065717A (ko) 2025-05-13
SI3408298T1 (sl) 2025-05-30
US20190307751A1 (en) 2019-10-10
ES3012491T3 (en) 2025-04-09
WO2017132661A3 (fr) 2017-08-31
IL286923B1 (en) 2024-12-01
AU2017211423A1 (en) 2018-09-06
SMT202500086T1 (it) 2025-03-12
EP3408298A4 (fr) 2019-09-04
JP7030701B2 (ja) 2022-03-07
CN115844895A (zh) 2023-03-28
EP3408298A2 (fr) 2018-12-05
BR112018015590A2 (pt) 2019-10-01
PL3408298T3 (pl) 2025-03-31
MX2018009227A (es) 2018-11-09
FI3408298T3 (fi) 2025-02-24
AU2022200583B2 (en) 2024-05-02
IL286923A (en) 2021-10-31
US11116771B2 (en) 2021-09-14
PT3408298T (pt) 2025-03-20
JP2026016502A (ja) 2026-02-03
JP2019511460A (ja) 2019-04-25
MA43879B1 (fr) 2025-02-28
EP3408298B1 (fr) 2024-11-20
CN109311980A (zh) 2019-02-05
US20220072001A1 (en) 2022-03-10
IL316540A (en) 2024-12-01
HUE070208T2 (hu) 2025-05-28
CA3013044A1 (fr) 2017-08-03

Similar Documents

Publication Publication Date Title
EP3408298A4 (fr) Modulation des récepteurs couplés aux protéines g (rcpg) par les imipridones
LT3689899T (lt) Mnd promotorių chimerinių antigenų receptoriai
HRP20251588T1 (hr) Pripravak koji sadrži protutijelo
DK3532486T3 (da) Antistof-forbundne cykliske peptidtyrosin-tyrosinforbindelser som modulatorer af neuropeptid-y- receptorer
EA201691974A1 (ru) Антитела против ox40 и способы их применения
DK3126499T3 (da) Sammensætninger til modulering af sod-1-ekspression
EP4227703C0 (fr) Technique de positionnement à bande ultra-large
DK3318754T3 (da) Trykgenererende indretning af Magnus-typen
DK3597663T3 (da) Kimære antigenreceptorer af anti-cd70
MX2016006725A (es) Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.
DK3831872T3 (da) Dæksel af termohærdet polymer til forsyningsbrønd
DK3119888T3 (da) Sammensætninger til at modulere ataxin-2-ekspression
DK3665173T3 (da) Ny fremgangsmåde til yntetisering af amanitiner
EP3552314A4 (fr) Conception de canal de contrôle efficace mettant en oeuvre des codes polaires
EP3604449A4 (fr) Composition de silicone durcissable par addition
EP3587231A4 (fr) Améliorations apportées à une bicyclette elliptique pliable
DK3125942T3 (da) Forstøvning af immunoglobulin
EP3419666A4 (fr) Thérapie par agonistes des récepteurs alpha-1-adrénergiques
DK2926897T3 (da) Anordning til genindvinding af halogenerede carbonhydrider
HUP1800333A2 (hu) GABAA A5 receptor modulátor hatású biciklusos vegyületek
DK3484880T3 (da) Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma
DK3448853T3 (da) Forbindelser til modulering af aquaporiner
IL271359A (en) Modulators of alpha-synuclein
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
DK2923690T3 (da) Sammensætning til stabilisering af lysfølsomme forbindelser